Stockholm - Delayed Quote ? SEK Medivir AB (publ) (MVIR.ST) Follow Compare 2.8000 +0.0100 (+0.36%) At close: October 18 at 5:24 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Medivir to present at the Pareto Securities Healthcare Conference Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the Pareto Securities Healthcare Conference tomorrow, September 19. PR Newswire ? last month MVIR.ST +0.36% Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, mature data from its ongoing phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima? in advanced liver cancer (hepatocellular carcinoma/HCC) at the ESMO (European Society of Medical Oncology) Congress in Barcelona, Spain. PR Newswire ? last month MVIR.ST +0.36% Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16 Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima? (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, September 16, 2024. PR Newswire ? last month MVIR.ST +0.36% Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, is pleased to announce that updated data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima? (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress in Barcelona, September 13-17, 2024. PR Newswire ? 3 months ago MVIR.ST +0.36% Number of shares and votes in Medivir AB on 28 June 2024 Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024. Both the issue and the reclassification have been previously announced through a separate press release. PR Newswire ? 3 months ago MVIR.ST +0.36% Fostrox + Lenvima? holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide (fostrox) + Lenvima? in advanced hepatocellular carcinoma (HCC) at the ESMO GI (European Society of Medical Oncology, Gastrointestinal Cancers) Cancers Congress in Munich, Germany. PR Newswire ? 3 months ago MVIR.ST +0.36% Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide (fostrox) + Lenvima? vs Lenvima alone in second line HCC. PR Newswire ? 3 months ago MVIR.ST +0.36% Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024 In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 7 May 2024 ("LTIP 2024"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 1,700,000 shares of series C, (ii) repurchase of the 1,700,000 shares of series C, (iii) reclassification of 114,587 shares of series C into ordinary shares and (iv) partial execution of the annual general meeting's resolution on transfer of own ordinary shares by tra PR Newswire ? 4 months ago MVIR.ST +0.36% Medivir to present at Redeye Growth Day Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at Redeye Growth Day, today May 30, 2024. PR Newswire ? 4 months ago MVIR.ST +0.36% Medivir′s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. PR Newswire ? 4 months ago TNGX MVIR.ST +0.36% Resolutions at the Annual General Meeting in Medivir on 7 May 2024 Medivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024. The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The annual general meeting in Medivir Aktiebolag (publ) resolved the following: PR Newswire ? 5 months ago MVIR.ST +0.36% MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. PR Newswire ? 5 months ago MVIR.ST +0.36% Medivir brings the Q1 webcast forward to 10 a.m. on April 30 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET. The webcast is brought forward as Nasdaq Stockholm closes earlier. PR Newswire ? 5 months ago MVIR.ST +0.36% FDA grants Medivir′s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) for the treatment of Legg-Calvé-Perthes Disease (LCPD). PR Newswire ? 5 months ago MVIR.ST +0.36% Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global phase 2b study and opening of an IND for fostroxacitabine bralpamide (fostrox) in the US. PR Newswire ? 5 months ago MVIR.ST +0.36% Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701 Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France, reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701. PR Newswire ? 6 months ago MVIR.ST +0.36% Medivir to present at Investing in Oncology Forum on April 10 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024. PR Newswire ? 6 months ago MVIR.ST +0.36% Medivir 2023 Annual Report published Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company's website: www.medivir.com. PR Newswire ? 6 months ago MVIR.ST +0.36% Notice of Annual General Meeting of Medivir AB (publ) The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 CEST at Helio GT30, Grev Turegatan 30, Stockholm, Sweden. PR Newswire ? 6 months ago MVIR.ST +0.36% Medivir to present at Swiss Nordic Bio in Zürich on March 7 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024. PR Newswire ? 7 months ago MVIR.ST +0.36% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return MVIR.ST OMX Stockholm 30 Index YTD -1.75% +8.18% 1-Year -46.03% +19.43% 3-Year -65.41% +12.07%
